Clinical medicine profile
Vildagliptin
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Obtain allergy and medication history.
- Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
- Use the lowest effective dose for the shortest appropriate duration.
- Monitor for expected class adverse effects.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
50mg BD. When used in with a sulphonylurea, the dose is 50mg OD in the morning.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Antidiabetic
Adverse effects
- Adverse reactions vary by agent.
- Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
- Report suspected ADRs via national pharmacovigilance channels.
Drug interactions
Open multi-drug checker ↗- Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
- Document allergy status and key interactions.
Mechanism & disposition
It is a dipeptidyl peptidase-4 [DPP-4] inhibitor that acts by inhibition of the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Read complete mechanism
It is a dipeptidyl peptidase-4 [DPP-4] inhibitor that acts by inhibition of the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| GALVUS MET 50 | Not recorded | 1000MG TABS 30*S | UnavailableDaima Chemist price-list reference |
| GALVUS MET TABS 50 | Not recorded | 500MG 30*S | UnavailableDaima Chemist price-list reference |
| GLUCOWELL | DAIMA BIASHARA / Wholesale Import | 50MG 28*S | KES 902.95daima_biashara_price_list |
| GLUCOWELL MET 50/1000 TABS 28*S | Not recorded | — | KES 1,053.30Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| JUSTEEZ 50 | Emcure Pharmaceuticals Ltd. | Tablet | Unavailable |
| VIGLIPTIN 50MG Tablet | DAWA LTD | Tablet 50MG | Unavailable |
| Viglita 50 Tablet | Square Pharmaceuticals Ltd. | Tablet | Unavailable |
| VILASON-50 | Unison Pharmaceuticals Pvt. Ltd. | Tablet | Unavailable |
| VILDA 100mg OD TABLETS | M/s. Innocia Lifesciences Pvt. Ltd. | Tablet 100mg | Unavailable |
| Vildaril 50 | Ajanta Pharma Limited | Tablet | Unavailable |
| Vildaril 100 | Ajanta Pharma Limited | Tablet | Unavailable |
| Vilget 50mg Tablets | Getz Pharma (Pvt.) Limited | Tablet 50mg | Unavailable |
| VINGLYN | Cadila Healthcare Ltd. | Tablet | Unavailable |
| VIVUS. | Laboratory & Allied Limited | Film-Coated Tablet | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.